IL6 and colitis: In a male C57BL/6 mouse model (Zhang et al., 2016), Naringin decreased interleukin-6 (IL-6) secretion by inhibiting the NF-κB/IL-6/STAT3 pathway, downregulated the expression of COX-2, myeloid-derived suppressor cells (MDSCs), proinflammatory mediators GM-CSF/M-CSF, and tumor necrosis factor-α (TNF-α), and increased the number of macrophages, CD4+ T and CD8+ T cells thereby slowing down the growth of colitis and colorectal adenoma cells and reducing the possibility of carcinogenesis.